Dr Sarah Wordsworth
BSc MSc PhD
Associate Professor and University Research Lecturer
Sarah Wordsworth joined the Health Economics Research Centre in January 2003 and has developed a research programme within HERC on the economics of genetic and genomic technologies. Of particular interest are the economics of translating genomic high-throughput technologies from research into clinical practice, in both cancer and cardiovascular disease. In October 2006, Sarah took up a post-doctoral fellowship from the National Institute for Health Research. This fellowship involved methodological and applied research on the economic evaluation of novel genomic technologies in the NHS. Sarah's other interests include costing methodology and trial based evaluations in the areas of eye disease, blood transfusion, cardiac surgery and surgery for obesity. Prior to this appointment, Sarah worked in the Health Economics Research Unit at the University of Aberdeen from 1995-2002, after completing her MSc in Health Economics in 1995 at the University of York.
The melanoma genomics managing your risk study: A protocol for a randomized controlled trial evaluating the impact of personal genomic risk information on skin cancer prevention behaviors.
Smit AK. et al, (2018), Contemp Clin Trials, 70, 106 - 116
Core Items for a Standardized Resource Use Measure: Expert Delphi Consensus Survey.
Thorn JC. et al, (2018), Value Health, 21, 640 - 649
Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals.
Morrell L. et al, (2018), BMC Health Serv Res, 18
Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature.
Schwarze K. et al, (2018), Genetics in medicine : official journal of the American College of Medical Genetics
Accurate costs of blood transfusion: a micro-costing of administering blood products in the United Kingdom National Health Service
Stokes EA. et al, (2018), Transfusion